Vera Therapeutics, Inc. (VERA): Price and Financial Metrics
VERA Price/Volume Stats
| Current price | $45.96 | 52-week high | $46.80 |
| Prev. close | $45.51 | 52-week low | $5.95 |
| Day low | $44.63 | Volume | 637,600 |
| Day high | $46.80 | Avg. volume | 1,624,494 |
| 50-day MA | $23.57 | Dividend yield | N/A |
| 200-day MA | $16.14 | Market Cap | 2.41B |
VERA Stock Price Chart Interactive Chart >
Vera Therapeutics, Inc. (VERA) Company Bio
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Latest VERA News From Around the Web
Below are the latest news stories about VERA THERAPEUTICS INC that investors may wish to consider to help them evaluate VERA as an investment opportunity.
Vera Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare ConferenceBRISBANE, Calif., Dec. 27, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunologic diseases, today announced that the Company’s management team will present at the 42nd Annual J.P. Morgan Healthcare Conference, which is taking place in San Francisco, CA from January 7 – 11, 2024. The management team will also participate in one-on-one inve |
This Promising Small-Cap Biotech Stock Could Rise 70%, According to Wall StreetIs the stock's risk worth the potential reward? |
Wall Street Analysts Believe Vera Therapeutics, Inc. (VERA) Could Rally 86.76%: Here's is How to TradeThe mean of analysts' price targets for Vera Therapeutics, Inc. (VERA) points to an 86.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
Vera Therapeutics Inc (VERA) Reports Q3 Financial Results and Business UpdatesContinued Progress in Clinical Trials and Strong Financial Position to Support Operations into Early 2026 |
Vera Therapeutics Provides Business Update and Reports Third Quarter Financial ResultsPhase 2b open-label extension eGFR and proteinuria data expected in the first quarter of 2024; actively adding sites and enrolling pivotal Phase 3 ORIGIN 3 study of atacicept in IgANAnnounced analysis of Phase 2b ORIGIN study showing resolution of hematuria in the majority of patients, at the American Society of Nephrology Kidney Week 2023Strong balance sheet expected to fund operations to early 2026 BRISBANE, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a la |
VERA Price Returns
| 1-mo | 207.84% |
| 3-mo | 239.69% |
| 6-mo | 159.66% |
| 1-year | 448.45% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 198.83% |
| 2023 | -20.52% |
| 2022 | -27.58% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...